Facilitated By

San Antonio Medical Foundation

Apixaban For The Reduction Of Thrombo-Embolism In Patients With Device-Detected Sub-Clinical Atrial Fibrillation

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Geneva
Research Start Date
Status
Active

This study is a prospective multicenter double-blind randomized controlled trial. It will recruit patients with SCAF (Sub-Clinical Atrial Fibrillation) detected by either a pacemaker, an ICD (implantable cardioverter defibrillator) or an insertable cardiac monitor (ICM); who also have other risk factors for stroke (previous stroke/TIA or systemic arterial embolism OR age ? 75 OR age 65-74 with ? 2 other risk factors OR age 55-64 with ? 3 other risk factors). Eligible and consenting patients will be randomized to receive aspirin or apixaban. The primary efficacy outcome is the composite of stroke and systemic arterial embolism. A total of 4000 patients will be enrolled from 70 or more clinical centers, with an anticipated mean follow-up of at least 36 months, with the precise termination of follow-up occurring once 248 verified/adjudicated primary efficacy outcome events have occurred.

Collaborative Project
Clinical Care
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.